Published in New England Journal of Medicine · View the paper (DOI)
Researchers found that adding immunotherapy before surgical removal of stage III-IV melanoma significantly improved event-free survival compared to standard-of-care treatment. The study showed that neoadjuvant therapy is superior to the same therapy given in the adjuvant setting.
Coverage from 2 institutions